Micro array patch (MAP) for the delivery of thermostable vaccines in Australia: A cost/benefit analysis.
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
received:
30
06
2021
revised:
03
08
2021
accepted:
05
08
2021
pubmed:
8
9
2021
medline:
25
2
2023
entrez:
7
9
2021
Statut:
ppublish
Résumé
It is anticipated that transforming the vaccine supply chain from syringe-and-needle to thermostable vaccines enabled by Micro Array Patch (MAP) will result in reduced supply chain costs as well as reduced wastes (environmental impact) and improved safety. This paper provides a thorough cost comparison of the conventional syringe-and-needle vaccine supply chain versus the MAP vaccine supply chain for influenza vaccine delivery in Australia. To determine the potential cost implications and general benefits of replacing syringe-and-needle flu vaccine with MAP-enabled thermostable flu vaccine in Australia. We first provide a snapshot of the existing flu vaccine supply chain in Australia including its limitations and opportunities for improvement. Data/information is collected through interviewing the key stakeholders across vaccine supply chain including vaccine manufacturers, logistics providers, clinics, hospitals, and pharmacies. A cost/benefit analysis of the anticipated supply chain of the MAP-enabled vaccine will reveal the opportunities and challenges of supply chain transformation for flu vaccine delivery in Australia. Our high-level practice-informed cost/benefit analysis identifies cold chain removal as an important source of cost saving, but administrative cost savings appear to be even more significant (e.g., time saving for nurses and those involved in cold chain management). Our analysis also identifies the key benefits and limitations of vaccine supply chain transformation in Australia. We conclude that the benefits of moving from syringe-and-needle vaccines to thermostable MAP-delivered vaccines are beyond transportation and storage cost saving. Potential benefits through cost saving, waste reduction, and service level improvement are discussed along with various safety and wellbeing consequences as well as directions for future research in this area.
Sections du résumé
BACKGROUND
It is anticipated that transforming the vaccine supply chain from syringe-and-needle to thermostable vaccines enabled by Micro Array Patch (MAP) will result in reduced supply chain costs as well as reduced wastes (environmental impact) and improved safety. This paper provides a thorough cost comparison of the conventional syringe-and-needle vaccine supply chain versus the MAP vaccine supply chain for influenza vaccine delivery in Australia.
OBJECTIVE
To determine the potential cost implications and general benefits of replacing syringe-and-needle flu vaccine with MAP-enabled thermostable flu vaccine in Australia.
METHODS
We first provide a snapshot of the existing flu vaccine supply chain in Australia including its limitations and opportunities for improvement. Data/information is collected through interviewing the key stakeholders across vaccine supply chain including vaccine manufacturers, logistics providers, clinics, hospitals, and pharmacies. A cost/benefit analysis of the anticipated supply chain of the MAP-enabled vaccine will reveal the opportunities and challenges of supply chain transformation for flu vaccine delivery in Australia.
FINDINGS
Our high-level practice-informed cost/benefit analysis identifies cold chain removal as an important source of cost saving, but administrative cost savings appear to be even more significant (e.g., time saving for nurses and those involved in cold chain management). Our analysis also identifies the key benefits and limitations of vaccine supply chain transformation in Australia.
CONCLUSION
We conclude that the benefits of moving from syringe-and-needle vaccines to thermostable MAP-delivered vaccines are beyond transportation and storage cost saving. Potential benefits through cost saving, waste reduction, and service level improvement are discussed along with various safety and wellbeing consequences as well as directions for future research in this area.
Identifiants
pubmed: 34489130
pii: S0264-410X(21)01036-7
doi: 10.1016/j.vaccine.2021.08.016
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6166-6173Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.